Elafibranor shows a broadly reassuring safety profile in patients with primary biliary cholangitis
Elafibranor shows a reassuring safety profile for patients with PBC
This meta-analysis of 274 patients with UDCA-inadequate-responder primary biliary cholangitis evaluated the safety of elafibranor compared t…
New data suggests the medication elafibranor is well tolerated by patients with primary biliary cholangitis who do not respond well to stand…
Seladelpar 10 mg shows optimal risk-benefit profile for UDCA-refractory primary biliary cholangitis patients
New data identifies promising treatments for primary biliary cholangitis
This network meta-analysis of 1,540 patients evaluates various therapies for primary biliary cholangitis (PBC) with inadequate response to U…
New research identifies specific medications that may improve liver health and relieve itching for patients with primary biliary cholangitis…
PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients
New drugs ease itch for patients whose current treatment fails
This systematic review and meta-analysis of 660 patients with primary biliary cholangitis and inadequate response to UDCA found that PPAR ag…
A review of six hundred sixty patients found new medicines significantly reduced itch scores in people with primary biliary cholangitis who …